Incyte (INCY) Change in Account Payables (2010 - 2026)
Incyte (INCY) reported Change in Account Payables of $23.4 million for Q1 2026, up 1186.1% on a YoY basis from $1.8 million in Q1 2025, and down 28.89% quarter-over-quarter from $33.0 million in Q4 2025.
Incyte (INCY) Change in Account Payables (2010 - 2026) Analysis & Trends
Incyte has reported Change in Account Payables for 17 years, with the latest figure at $23.4 million in Q1 2026.
- For the quarter ending Q1 2026, Change in Account Payables rose 1186.1% year-over-year to $23.4 million; the trailing twelve-month figure through Mar 2026 stood at $32.2 million (up 2.57% YoY), and the FY2025 full-year result was $6.6 million, down 92.56% from the prior year.
- Change in Account Payables for Q1 2026 stood at $23.4 million, down from $33.0 million in the prior quarter.
- The five-year high for Change in Account Payables was $114.4 million in Q4 2022, with the low at -$221.9 million in Q1 2023.
- Historically, Change in Account Payables has averaged $3.3 million across 5 years, with a median of $19.0 million in 2024.
- Annual changes were most pronounced in 2023 — Change in Account Payables sank 1034.35% — and 2026, when it soared 1186.1%.
- Incyte's Change in Account Payables stood at $114.4 million in 2022, then plunged by 126.06% to -$29.8 million in 2023, then soared by 163.9% to $19.0 million in 2024, then soared by 73.1% to $33.0 million in 2025, then fell by 28.89% to $23.4 million in 2026.
- The last three Change in Account Payables figures came in at $23.4 million (Q1 2026), $33.0 million (Q4 2025), and -$44.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -3.26 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 35.60 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -9.42 Mn |
| 10 | Incyte | 19.62 Bn | 15.60 Bn | 1.17 Bn | 23.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 23.45 Mn |
| Mar 31, 2026 | 23.45 Mn |
| Dec 31, 2025 | 32.98 Mn |
| Dec 31, 2025 | 32.98 Mn |
| Sep 30, 2025 | -44.17 Mn |
| Sep 30, 2025 | -44.17 Mn |
| Jun 30, 2025 | 19.91 Mn |
| Jun 30, 2025 | 19.91 Mn |
| Mar 31, 2025 | -2.16 Mn |
| Mar 31, 2025 | -2.16 Mn |
| Dec 31, 2024 | 19.05 Mn |
| Dec 31, 2024 | 19.05 Mn |
| Sep 30, 2024 | 30.54 Mn |
| Sep 30, 2024 | 30.54 Mn |
| Jun 30, 2024 | -16.06 Mn |
| Jun 30, 2024 | -16.06 Mn |
| Mar 31, 2024 | 54.64 Mn |
| Mar 31, 2024 | 54.64 Mn |
| Dec 31, 2023 | -29.81 Mn |
| Dec 31, 2023 | -29.81 Mn |